Prospect for Covid-19 Investigational Drugs: The Timeline (Prospect for Covid-19 Therapeutics)


Authors : Augustine S. Samorlu

Volume/Issue : Volume 7 - 2022, Issue 8 - August

Google Scholar : https://bit.ly/3IIfn9N

Scribd : https://bit.ly/3CRkV2f

DOI : https://doi.org/10.5281/zenodo.7045400

An outbreak of Coronavirus disease-2019 (COVID-19), firstly reported in Wuhan, China in December 2019, and eventually turned into pandemic, is continuing to put a lot of burden on the health sectors worldwide. Thus, finding a fast and effective therapy is crucial to discontinue the current human-to-human transmission and to treat serious cases. Several active preclinical and clinical studies are going on towards these goals, while existing drugs are being used alone and in combination to treat symptoms in COVID-19 patients. Here, bearing in mind the timeline and various stages of drug development, and considering the extremely-low probability that any new biological target or molecule identified as potentially relevant to the SARS-CoV-2 will result in an approved new medicine, a brief look at those basic studies and clinical trials of the investigational drugs and projected success of COVID-19 therapeutics based on the unprecedented rapidity of the processes being witnessed were emphasized. Despite the current explosion in such studies, from an expert opinion, it is believed that concerted and efficient development plans may ultimately yield a fast and effective medicine for the disease or we may live with the disease (COVID-19).

Keywords : SARS-Cov-2, COVID-19, Clinical Trials, Therapeutics, Drug Development

CALL FOR PAPERS


Paper Submission Last Date
29 - February - 2024

Paper Review Notification
In 1-2 Days

Paper Publishing
In 2-3 Days

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe